Trump's New Executive Orders May Hit Indian Pharma Exports

The recent executive orders on pharma issued by President Donald Trump are expected to create significant challenges for Indian pharmaceutical companies, especially those operating in the U.S. generic drug market, according to a report by Nuvama Research.

- TDG NETWORK

These policy moves aim to prioritize domestic manufacturing of pharmaceuticals in the United States and could reshape global drug supply chains if implemented strictly.

The report said, "The new development, if fully implemented, can disrupt and reshape global pharma supply chains. Over the past few months, we have been observing announcements of the cumulative USD15bn capex plans in the US by innovative pharma companies."

India, known as the "pharmacy of the world," has long enjoyed a cost advantage in manufacturing drugs, particularly generics. Many Indian companies export medicines to the U.S., benefiting from lower operational costs.